Is a Non-Depolarising Suxamethonium an Achievable Target?

  • R. J. Marshall
  • A. W. Muir
Conference paper


Although suxamethonium is still widely used in anaesthesia, its use is frequently associated with many side-effects, most of which (e.g. fasciculations, muscle pain) can be directly attributed to its depolarising mechanism of action. In addition, prolonged neuromuscular blockade (and apnoea) is produced in a small cohort of patients who have an atypical cholinesterase. Lastly the inability to reverse suxamethonium-induced block with an anticholinesterase may produce a potentially dangerous clinical situation in the event of difficulties with intubation. Thus the discovery of a nondepolarising neuromuscular blocking agent possessing the rapid onset/short duration profile of suxamethonium has been a major goal for interested scientists for many years (see Hughes, 1984 and Marshall et al, 1992 for brief reviews).


Neuromuscular Blocking Nictitate Membrane Neuromuscular Blocking Agent Nictitate Membrane Neuromuscular Blocking Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Agoston, S. Houwertjes, M.C. & Salt, P.J. (1980). A new method for measuring hepatic uptake of drugs and their pharmacodynamic effects in anaesthetised cats. Br. J. Pharmac. 68, 637–643.CrossRefGoogle Scholar
  2. Baird, W.L.M. (1974). Initial studies in man with a new myoneural blocking agent (Org 6368). Br. J. Anaesth. 46, 658–661.PubMedCrossRefGoogle Scholar
  3. Bamford, D.G., Briggs, D.F., Davis, M. & Parnell, E. (1967). Neuromuscular blocking properties of stereometric androstane-3,17-bisqua ternary ammonium salts. Br. J. Pharmacol. Chemother., 30192–202.CrossRefGoogle Scholar
  4. Briggs, D.F., Davis, M. & Wien, R. (1964). Muscle relaxant properties of a steroid bis-quaternary ammonium salt. Experientia 20, 119–121.CrossRefGoogle Scholar
  5. Blogg, C.E., Savege, T.M., Simpson, J.C., Ross, L. & Simpson, B.R. (1973). A new muscle relaxant, AH 8165. Proc. Roy. Soc. Med. 66, 1023–1027.PubMedGoogle Scholar
  6. Bowman, W.C., Rodger, I.W., Houston, J., Marshall, R.J. & Mclnderar, I. (1988). Structure: action relationships among some desacetoxy analogues of pancuronium and vecuronium in the anaesthetised cat. Anaesthesiology 69, 57–62.CrossRefGoogle Scholar
  7. Brittain, R.T. & Tyers, M.B. (1973). The pharmacology of AH 8165: a rapidacting, short lasting competetive neuromuscular blocking drug. Br. J. Anaesth.45, 837–843.PubMedCrossRefGoogle Scholar
  8. Buckett, W.R. & Saxena, P. (1969). The pharmacology of dacuronium bromide — a new short-acting neuromuscular blocking drug of non-depolarising type. Abstr. IVth In. Congress in Pharmacology (Basel) 420.Google Scholar
  9. Busfield, D., Child, K.J., Clark, A.J., Davis, B & Dossa, M.G. (1968). Neuromuscular blocking activities of some steroidal mono-and bis-qua ternary ammonium compounds with special reference to Nl,N1-dimethylconessine. Br. J. Pharmacol. Chemother. 32, 609–623.PubMedCrossRefGoogle Scholar
  10. Feldman, S.A. & Tyrell, M.F. (1970). A steroidal muscle relaxant NB68. Anaesthesia, 25349–365.PubMedCrossRefGoogle Scholar
  11. Frampton, J.E. & McTavish, D. (1993). Mivacurium. A review of its pharmacology and therapeutic potential in general anaesthesia. Drugs 45, 1066–1089.PubMedCrossRefGoogle Scholar
  12. Hughes, R. (1984). Experimental and clinical evaluation of neuromuscular blocking agents. J. Pharmacol. Methods. 12, 1–27.PubMedCrossRefGoogle Scholar
  13. Kopman, A.F. (1989). Pancuronium, gallamine and d-tubocurarine compared — is the speed of onset related to drug potency? Anaesthesiology 71, 915–920.CrossRefGoogle Scholar
  14. Krieg, N., Crul, J.F. & Booij, L.H.D.J. (1980). Relative potency of Org NC 45, pancuronium, alcuronium and tubocurarine in anaesthetised man. Br. J. Anaesth. 52, 783–787.PubMedCrossRefGoogle Scholar
  15. Marshall, R.J., Muir, A.W., Sleigh, T. & the late D.S. Savage (1992). The search for the non-depolarising equivalent of suxamethonium. In: the Development of Amino-steroidal Neuromuscular Blocking Agents pp21–38. Ed. P. Denissen. Interface, Turnhout.Google Scholar
  16. Muir, A.W. & Marshall, R.J. (1987). Comparative neuromuscular blocking effects of vecuronium, pancuronium, Org 6368 and suxamethonium in the anaesthetised domestic pig. Br. J. Anaesth. 59, 622–629.PubMedCrossRefGoogle Scholar
  17. Muir, A.W., Houston, J., Marshall, R.J., Bowman, W.C. & Marshall, I.G. (1994). A comparison of the neuromuscular blocking and autonomic effects of two short-acting muscle relaxants with these of succinylcholine in the anaesthetised cat and pig. Anaesthesiology 70, 533–540.CrossRefGoogle Scholar
  18. Mushin, W.W. & Mapleson, W.W. (1964). Relaxant action in man of dipyrandium cloride (M&B 9105A). Br. J. Anaesth. 36, 761–769.PubMedCrossRefGoogle Scholar
  19. Norman, J. & Katz, R.L. (1971). Some effects of the steroidal muscle relaxant, dacuronium bromide, in anaesthetised patients. Br. J. Anaesth. 43, 313–318.PubMedCrossRefGoogle Scholar
  20. Sugrue, M.F., Duff, N. & Mclndewar, I. (1975). On the pharmacology of Org 6368 (2β-dipiperidino-5α-androstan-3α-ol acetate dimethobromide), a new steroidal neuromuscular blocking agent. J. Pharm. Pharmac. 27, 721–727.CrossRefGoogle Scholar
  21. van den Broek, L. & Wierda, J.M.K.H. (1993). Org 7617, a short-acting nondepolarising neuromuscular relaxant. Acta Anaesth. Scan. Suppl. 100, 37, Abstr. 084.Google Scholar
  22. Wierda, J.M.K.H., van den Broek, L., Proost, J.H., Verbaan, B.W. & Hennis, P.J. (1993). Time course of action and endotracheal intubating conditions of Org 9487, a new short-acting steroidal muscle relaxant; a comparison with succinylcholine. Anaesth. Analges. 77, 579–584.Google Scholar
  23. Wierda, J.M.K.H., Beaufort, A.M., Kleef, U.W., Smeulers, N.J. & Agoston, S. (1994). Preliminary investigations of the clinical pharmacology of three short-acting non-depolarising neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. Can. J. Anaesth. 41, 213–220.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 1995

Authors and Affiliations

  • R. J. Marshall
    • 1
  • A. W. Muir
    • 1
  1. 1.Scientific Development GroupOrganon Laboratories LimitedLanarkshireUK

Personalised recommendations